Schedule 13D ownership disclosure

Eloxx Pharmaceuticals, Inc.

Security class unavailable · CUSIP: 29014R103

Event date: 2021-04-01

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
2,532,270
Percent of class
6.3000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001062993-21-003594
Form type
SC 13D
Filer
Advent Life Sciences LLP
CIK
CIK 1601364
Filed
Apr 13, 2021
Reporting period
Apr 01, 2021
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub